U.K.-based drugmaker GlaxoSmithKline PLC will slash about 650 jobs in the U.S. as part of a previously announced restructuring, Reuters reported, citing a company spokeswoman.
The cuts will include 450 sales positions and about 100 back office jobs from each of the Philadelphia and at Research Triangle Park, N.C., locations. The company has about 15,000 employees in the U.S.
Savings generated will go toward research and development and commercial support of new products, spokeswoman Mary Anne Rhyne said.
CEO Emma Walmsley revealed a restructuring program in July that will lead to projected cost savings of £400 million a year by 2021.